Literature DB >> 29423660

Targeting Suppressive Oligonucleotide to Lymph Nodes Inhibits Toll-like Receptor-9-Mediated Activation of Adaptive Immunity.

Chunsong Yu1, Myunggi An1, Evan Jones2, Haipeng Liu3,4,5.   

Abstract

PURPOSE: This paper aims to investigate the immunoinhibitory properties of a lymph nodes-targeting suppressive oligonucleotide (ODN) for the potential treatment of autoimmune diseases or chronic inflammation.
METHODS: Synthetic suppressive ODN engineered with an albumin-binding diacyl lipid at the 5'-terminal (lipo-ODN) was synthesized. In vitro and in vivo experiments were designed to compare the immune suppressive properties of lipo-ODN and unmodified ODN. Cellular uptake and distribution, inhibition of Toll-like receptor (TLR) activation, lymph nodes (LN) draining, and the suppression of antigen-specific immune responses in an ovalbumin protein model was investigated.
RESULTS: Compared to unmodified ODN, lipid functionalized suppressive ODN demonstrated enhanced cellular uptake and TLR-9 specific immune suppression in TLR reporter cells. Additionally, injection of a low dose of lipid-modified suppressive ODN, but not the unconjugated ODN, accumulated in the draining LNs and exhibited potent inhibition of antigen-specific CD8+ T cell and B cell responses in vivo.
CONCLUSIONS: Targeting suppressive ODN to antigen presenting cells (APCs) in the local LNs is an effective approach to amplify the immune modulation mediated by ODN containing repetitive TTAGGG motif. This approach might be broadly applicable to target molecular adjuvants to the key immune cells in the LNs draining from disease site, providing a simple strategy to improve the efficacy of many molecular immune modulators.

Entities:  

Keywords:  CpG-induced activation; albumin hitchhiking; immune suppressive ODN; immunosuppression; lipid conjugation

Mesh:

Substances:

Year:  2018        PMID: 29423660      PMCID: PMC6134838          DOI: 10.1007/s11095-018-2344-2

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  31 in total

1.  Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation.

Authors:  Ihsan Gursel; Mayda Gursel; Hiroshi Yamada; Ken J Ishii; Fumihiko Takeshita; Dennis M Klinman
Journal:  J Immunol       Date:  2003-08-01       Impact factor: 5.422

Review 2.  From sewer to saviour - targeting the lymphatic system to promote drug exposure and activity.

Authors:  Natalie L Trevaskis; Lisa M Kaminskas; Christopher J H Porter
Journal:  Nat Rev Drug Discov       Date:  2015-10-16       Impact factor: 84.694

3.  IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis.

Authors:  Deepak M W Balak; Martijn B A van Doorn; Robert D Arbeit; Rianne Rijneveld; Erica Klaassen; Tim Sullivan; Julie Brevard; Hok Bing Thio; Errol P Prens; Jacobus Burggraaf; Robert Rissmann
Journal:  Clin Immunol       Date:  2016-11-20       Impact factor: 3.969

4.  Active macromolecule uptake by lymph node antigen-presenting cells: a novel mechanism in determining sentinel lymph node status.

Authors:  M B Faries; I Bedrosian; C Reynolds; H Q Nguyen; A Alavi; B J Czerniecki
Journal:  Ann Surg Oncol       Date:  2000-03       Impact factor: 5.344

Review 5.  TLR-dependent T cell activation in autoimmunity.

Authors:  Kingston H G Mills
Journal:  Nat Rev Immunol       Date:  2011-11-18       Impact factor: 53.106

6.  Design of Polyelectrolyte Multilayers to Promote Immunological Tolerance.

Authors:  Lisa H Tostanoski; Yu-Chieh Chiu; James I Andorko; Ming Guo; Xiangbin Zeng; Peipei Zhang; Walter Royal; Christopher M Jewell
Journal:  ACS Nano       Date:  2016-09-07       Impact factor: 15.881

Review 7.  Phosphorothioate oligonucleotides: effectiveness and toxicity.

Authors:  Tommaso Iannitti; Julio Cesar Morales-Medina; Beniamino Palmieri
Journal:  Curr Drug Targets       Date:  2014       Impact factor: 3.465

Review 8.  Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9.

Authors:  Petar S Lenert
Journal:  Mediators Inflamm       Date:  2010-05-18       Impact factor: 4.711

Review 9.  Toll-like receptors.

Authors:  Kiyoshi Takeda; Tsuneyasu Kaisho; Shizuo Akira
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

10.  Structure-based programming of lymph-node targeting in molecular vaccines.

Authors:  Haipeng Liu; Kelly D Moynihan; Yiran Zheng; Gregory L Szeto; Adrienne V Li; Bonnie Huang; Debra S Van Egeren; Clara Park; Darrell J Irvine
Journal:  Nature       Date:  2014-02-16       Impact factor: 49.962

View more
  2 in total

1.  Engineering release kinetics with polyelectrolyte multilayers to modulate TLR signaling and promote immune tolerance.

Authors:  Lisa H Tostanoski; Haleigh B Eppler; Boyan Xia; Xiangbin Zeng; Christopher M Jewell
Journal:  Biomater Sci       Date:  2019-02-26       Impact factor: 6.843

Review 2.  DNA Nanostructure as an Efficient Drug Delivery Platform for Immunotherapy.

Authors:  Qingjia Chi; Zichang Yang; Kang Xu; Chunli Wang; Huaping Liang
Journal:  Front Pharmacol       Date:  2020-01-28       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.